Its mission is to discover and develop new treatments for neglected diseases and other poverty related conditions, and to ensure that patients in the most vulnerable countries enjoy equitable access to the results. In view of the circumstances of this target public, the "ideal" treatment should be oral, safe, effective, low cost, and short course. "Diagnosis should be simple," Pécoul points out, "while the idea that treatments should preferably be oral and short course is so patients do not have to travel for hours or even days to have the drug administered in a hospital center."
DNDi's strategy is to detect the need for a particular treatment, then coordinate and synergize the efforts of public and private partners – including pharmaceutical companies – in its development, production and distribution. Pécoul talks about its relationship with the pharma industry: "We have signed contracts with numerous laboratories, some of them at quite early development stages, and I can say that these relationships have worked well. They know that they are not going to make a profit, but the projects are supported by the people in their own teams and they are also aware that the countries affected are the market of the future."
Since it was founded, DNDi has come up with six new treatments for forgotten patients by improving, reformulating or combining existing drugs.
These include two treatments against malaria – ASAQ, developed in partnership with Sanofi, manufactured in Africa and distributed in 32 countries, and ASMQ, based on a technology transferred fro
|SOURCE BBVA Foundation|
Copyright©2012 PR Newswire.
All rights reserved